

Supporting information

Stereodivergent Synthesis of Trisubstituted Enamides: Direct Access to Both Pure Geometrical Isomers.

Luca Massaro^a, Jianping Yang^a, Suppachai Krajangsri^a, Emanuele Silvi^a, Thishana Singh^b,
Pher G. Andersson*^{a,b}

Corresponding author: pher.andersson@su.se

^aDepartment of Organic Chemistry, Stockholm University, Svante Arrhenius väg 16C, SE-10691 Stockholm, Sweden.


^bSchool of Chemistry and Physics, University of KwaZulu-Natal, Private Bag X54001, Durban, 4000, South Africa.

Table of contents:

1. Conditions screening for synthesis of (<i>Z/E</i>)-enamides.....	S2
2. Additional data for (<i>Z</i>)- α,β -enecarbamates.....	S4
2. Additional data for (<i>E</i>)- α,β -enecarbamates.....	S8
3. (<i>E</i>)- and (<i>Z</i>)- isomer energies.....	S13
4. NMR spectra of new compounds.....	S15
5. References.....	S73

1. Conditions screening for synthesis of (*Z/E*)-enamides.

Table S1. Screening of Brønsted acid conditions for synthesis of (*Z*)-enamides


Entry	catalyst (mol%)	Oxazolidinone (eq)	cat., solvent reflux		
				d.r. [<i>E</i> : <i>Z</i>]	conv. [%]
1	NH(Tf) ₂ (10)	2	toluene	33:67	4
2	TfOH(10)	2	toluene	19:81	8
3	SI- <i>p</i> -TSA ^[a] (10)	2	toluene	17:83	6
4	PTSA(10)	2	cyclohexane	10:90	3
5	PTSA(10)	2	DME	23:77	6
6	H ₂ SO ₄ (10)	2	toluene	22:78	4
7	CSA ^[b] (10)	2	toluene	25:75	16
8	PTSA(10)	2	toluene	15:85	40
9	PTSA(10)	2	PhCF ₃	21:79	35
10	PTSA(10)	2	Benzene	11:89	30
11	PTSA(10)	3	PhEt	28:72	17
12	PTSA(5)	3	toluene	14:86	31
13	PTSA(20)	3	toluene	18:82	46
14 ^[c]	PTSA(10)	3	toluene	15:85	50
15 ^[d]	PTSA(10)	3	toluene	-	nr
16 ^[e]	PTSA(10)	3	toluene	-	nr

Standard condition: 3 equiv. oxazolidinone, 10 mol% *p*-TSA,

Dean Stark. ^[a] SI-*p*-TSA= *p*-Toluenesulfonic acid on silica;

^[b] CSA= Camphor sulfonic acid; ^[c] Reaction time of 36 h.

^[d] Addition of molecular sieves 3 Å. ^[e] Addition of 1 equiv. of Na₂SO₄.

Table S2. Screening of Lewis acid conditions for synthesis of (*E*)-enamides

Entry	Oxazolidinone (equiv)	L.A. (equiv)	Base (equiv)	d.r. [<i>E</i> : <i>Z</i>]	conv. [%]
1	0.9	$\text{AlCl}_3(1.2)$	-	-	nr
2	0.9	$\text{TiCl}_4(1.2)$	-	-	nr
3	0.9	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	98:2	38
4	2	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	97:3	44
5	3	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	97:3	55
6	3	$\text{TiCl}_4(2.4)$	$\text{NEt}_3(10)$	96:4	50
7 ^[a]	3	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	96:4	38
8	p.w. ^[b]	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	98:2	31
9	5	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	97:3	45
10	3	$\text{TiCl}_4(5)$	$\text{NEt}_3(15)$	96:4	49
11 ^[c]	3	$\text{TiCl}_4(1.2)$	$\text{NEt}_3(5)$	97:3	30
12	6	$\text{TiCl}_4(2.4)$	$\text{NEt}_3(10)$	96:4	58

^[a] Addition of molecular sieves 3 Å; ^[b] **1** added in portion of 0.2 equiv. each minutes; ^[c] **2a** added with syringe pump (0.3 equiv./h.).

2. Additional data for (*Z*)-enecarbamates.

Table S3. Substrates scope for (*Z*)-enamides

Entry	Enamide	Yield ^a [%]	Recovered s.m. ^b [%]
		Corrected Yield ^c [%]	
1		21	67
2		46	53
3		24	70
4		45	39
5		19	60
6		24	55
7		11	83
8		5	92
9		19	76


Standard condition: 3 equiv. oxazolidinone, 10 mol% *p*-TSA, Dean Stark; ^aIsolated yield; ^bIsolated amount of ketones after purification; ^cYield corrected by recovered starting material.

Characterization NMR data of new α,β -enecarbamates not present in the manuscript (*Z*-isomer).




(*Z*)-3-(1-(3-bromophenyl)pent-1-en-1-yl)oxazolidin-2-one (3sa)

Colorless oil, 0.649g (21% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.50 (t, *J* = 1.8 Hz, 1H), 7.44 (dt, *J* = 7.5, 1.9, 1.4 Hz, 1H), 7.31 – 7.20 (m, 2H), 6.04 (t, *J* = 7.2 Hz, 1H), 4.57 – 4.45 (m, 2H), 3.74 – 3.64 (m, 2H), 2.22 (q, *J* = 7.3 Hz, 2H), 1.61 – 1.50 (m, 2H), 1.00 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 156.4, 138.2, 132.7, 132.1, 131.2, 130.2, 128.9, 124.4, 122.9, 62.3, 45.7, 30.4, 22.0, 14.1. HRMS (ESI-TOF) calcd for C₁₄H₁₆BrNO₂Na [M+Na]⁺:332.0257, found: 332.0265.




(Z)-3-(1-phenylprop-1-en-1-yl)oxazolidin-2-one(3sb)

Yellow oil, 0.934g (46% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.40 – 7.31 (m, 5H), 6.11 (q, J = 7.0 Hz, 1H), 4.54 – 4.47 (m, 2H), 3.71 – 3.65 (m, 2H), 1.86 (d, J = 7.0 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, CDCl₃) δ 156.3, 135.8, 134.8, 128.7, 128.2, 125.8, 124.9, 62.3, 45.4, 13.9. HRMS (ESI-TOF) calcd for C₁₂H₁₃NO₂Na [M+Na]⁺: 226.0838, found: 226.0828.




(Z)-3-(1-phenylhex-1-en-1-yl)oxazolidin-2-one(3sc)

White solid, mp 61.9–64.2 °C, 0.588g (24% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.41 – 7.27 (m, 5H), 6.00 (t, J = 7.2 Hz, 1H), 4.52 – 4.37 (m, 2H), 3.70 – 3.56 (m, 2H), 2.23 (q, J = 7.3 Hz, 2H), 1.58 – 1.26 (m, 5H), 0.93 (t, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.6, 136.0, 133.8, 130.9, 128.8, 128.3, 126.0, 62.4, 45.8, 31.2, 28.1, 22.7, 14.1. HRMS (ESI-TOF) calcd for C₁₅H₁₉NO₂Na [M+Na]⁺: 268.1308, found: 268.1301.




(Z)-3-(1-(4-chlorophenyl)prop-1-en-1-yl)oxazolidin-2-one(3sd)

White solid, mp 78.8–81.9 °C, 1.066g (45% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.3 – 7.3 (m, 2H), 7.3 – 7.2 (m, 2H), 6.1 (q, J = 7.0 Hz, 1H), 4.6 – 4.4 (m, 2H), 3.7 – 3.6 (m, 2H), 1.8 (d, J = 7.1 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.3, 134.5, 134.1, 134.1, 129.0, 127.2, 125.7, 62.4, 45.5, 14.1. HRMS (ESI-TOF) calcd for C₁₂H₁₂ClNO₂Na [M+Na]⁺: 260.0449, found: 260.0448.




(Z)-3-(1-(4-(trifluoromethyl)phenyl)prop-1-en-1-yl)oxazolidin-2-one(3se)

Yellow oil, 0.515g (19% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.63 – 7.59 (m, 2H), 7.48 – 7.41 (m, 2H), 6.20 (q, J = 7.0 Hz, 1H), 4.55 – 4.49 (m, 2H), 3.70 – 3.64 (m, 2H), 1.88 (d, J = 7.0 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.3, 139.6, 134.0, 130.2 (q, J = 32.6 Hz), 127.5, 126.1, 125.8 (q, J = 3.7 Hz), 124.1 (q, J = 272.0 Hz), 62.5, 45.5, 14.1. HRMS (ESI-TOF) calcd for C₁₃H₁₂F₃NO₂Na [M+Na]⁺: 294.0712, found: 297.0725.




(Z)-3-(1-(4-methoxyphenyl)prop-1-en-1-yl)oxazolidin-2-one(3sf)

Colorless oil, 0.560g (24% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.26 (dd, J = 6.4, 2.4 Hz, 3H), 6.90 – 6.85 (m, 2H), 5.96 (q, J = 7.0 Hz, 1H), 4.52 – 4.44 (m, 2H), 3.81 (s, 3H), 3.69 – 3.62 (m, 2H), 1.81 (d, J = 7.0 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 159.8, 156.4, 134.6, 128.6, 127.3, 123.1, 114.2, 62.4, 55.5, 45.6, 14.0. HRMS (ESI-TOF) calcd for C₁₃H₁₅NO₃Na [M+Na]⁺: 256.0944, found: 256.0940.




(Z)-3-(1-(4-chlorophenyl)-2-phenylvinyl)oxazolidin-2-one(3sg)¹

0.329g (11% yield). The compound is in agreement with reported data.¹



(Z)-3-(2-(4-chlorophenyl)-1-phenylvinyl)oxazolidin-2-one(3sh)¹
0.150g (5% yield). The compound is in agreement with reported data.¹













(Z)-3-(1-(m-tolyl)pent-1-en-1-yl)oxazolidin-2-one(3si)

Colorless oil, 0.466g (19% yield). ¹H NMR (400 MHz, Chloroform-d) δ 7.31 – 7.19 (m, 1H), 7.20 – 7.09 (m, 3H), 6.01 (t, J = 7.2 Hz, 1H), 4.55 – 4.40 (m, 2H), 3.73 – 3.61 (m, 2H), 2.38 (d, J = 0.7 Hz, 3H), 2.23 (q, J = 7.3 Hz, 2H), 1.66 – 1.51 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). ¹³C{¹H} NMR (101 MHz, Chloroform-d) δ 156.5, 138.3, 135.9, 134.0, 130.4, 129.0, 128.6, 126.5, 123.1, 62.2, 45.7, 30.3, 22.1, 21.5, 14.1. HRMS (ESI-TOF) calcd for C₁₅H₁₉NO₂Na [M+Na]⁺: 268.1308, found: 268.1303.

Table S4: E and Z isomers ratio of the Brønsted Acid reactions before isolation of the products

Entry	Enamide	d.r. (E:Z)	Entry	Enamide	d.r. (E:Z)
1		15:85	14		14:86
2		20:80	15		10:90
3		10:90	16		12:88
4		20:80	17		15:85
5		16:84	18		14:86
6		20:80	19		20:80
7		13:87	20		18:82
8		1:99	21		20:80

9		4:96	22		8:92
10		20:80	23		9:91
11		12:88	24		8:92
12		16:84	25		20:80
13		12:88	26		20:80

2. Additional data for (*E*)-enecarbamates.


Table S5. Substrates scope for (*E*)-enamides

The reaction scheme shows the conversion of enecarbamates **2sa-sh** to enecarbamates **3sa'-sh'**. The starting materials **2sa-sh** are substituted enecarbamates where the carbamate group is attached to an *E*-alkene. They react with Oxazolidinone in the presence of TiCl₄ and Et₃N to yield the corresponding enecarbamates **3sa'-sh'**, where the carbamate group is now attached to a *Z*-alkene.

Entry	Enamide	Yield ^a [%]	Recovered s.m. ^b [%]	Corrected Yield ^c [%]	Entry	Enamide	Yield [%]	Recovered s.m. ^b [%]	Corrected Yield[%]
1		23	52	48	5		26	59	63
2		38	52	79	6		46	48	89
3		44	51	90	7		27	62	71
4		35	46	77	8		40	54	87

Standard condition: 3 equiv. oxazolidinone, 1.2 equiv. TiCl₄, 5 equiv. NEt₃, 0-r.t.; ^a Isolated yield; ^b Isolated amount of ketones after purification; ^c Yield corrected by recovered starting material.

Characterization NMR data of new α,β -enecarbamates not present in the manuscript (*E*-isomer)



(*E*)-3-(1-(3-bromophenyl)pent-1-en-1-yl)oxazolidin-2-one(3sa')

Yellow oil, 0.710g (23% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.45 (ddd, *J* = 7.7, 2.0, 1.4 Hz, 1H), 7.40 (t, *J* = 1.8 Hz, 1H), 7.27 – 7.18 (m, 2H), 5.81 (t, *J* = 7.8 Hz, 1H), 4.37 – 4.29 (m, 2H), 3.61 – 3.54 (m, 2H), 2.06 (q, *J* = 7.5 Hz, 2H), 1.43 (h, *J* = 7.3 Hz, 2H), 0.89 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (101 MHz, Chloroform-*d*) δ 156.3, 136.8, 133.4, 131.7, 131.3, 130.0, 127.6, 126.3, 61.6, 46.1, 29.9, 23.0, 13.7. HRMS (ESI-TOF) calcd for C₁₄H₁₆BrNO₂Na [M+Na]⁺: 332.0257 (⁷⁹Br), found: (⁷⁹Br) 332.0240.




(*E*)-3-(1-phenylprop-1-en-1-yl)oxazolidin-2-one(3sb')

Yellow oil, 0.771g (38% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.41 – 7.27 (m, 5H), 5.96 (q, J = 7.2 Hz, 1H), 4.35 – 4.28 (m, 2H), 3.57 – 3.51 (m, 2H), 1.76 (d, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.7, 135.0, 134.3, 128.9, 128.5, 128.2, 120.6, 61.5, 46.1, 13.9. HRMS (ESI-TOF) calcd for $\text{C}_{12}\text{H}_{13}\text{NO}_2\text{Na} [\text{M}+\text{Na}]^+$: 226.0838, found: 226.0841.




(E)-3-(1-phenylhex-1-en-1-yl)oxazolidin-2-one(3sc')

Colorless oil, 1.078g (44% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.42 – 7.29 (m, 3H), 7.29 – 7.23 (m, 2H), 5.86 (t, J = 7.8 Hz, 1H), 4.35 – 4.25 (m, 2H), 3.60 – 3.45 (m, 2H), 2.10 (q, J = 7.6 Hz, 2H), 1.47 – 1.18 (m, 4H), 0.84 (t, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.6, 134.8, 134.5, 129.0, 128.5, 128.3, 126.0, 61.6, 46.2, 32.1, 27.9, 22.4, 14.0. HRMS (ESI-TOF) calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_2\text{Na} [\text{M}+\text{Na}]^+$: 268.1308, found: 268.1307.




(E)-3-(1-(4-chlorophenyl)prop-1-en-1-yl)oxazolidin-2-one(3sd')

White solid, mp 77.5-77.7 °C, 0.830g (35% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.37 – 7.30 (m, 2H), 7.23 – 7.14 (m, 2H), 5.88 (q, J = 7.2 Hz, 1H), 4.35 – 4.23 (m, 2H), 3.63 – 3.49 (m, 2H), 1.72 (d, J = 7.5 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.5, 138.3, 134.3, 129.4, 125.5 (q, J = 4.0, 3.5 Hz), 122.7, 121.3, 61.7, 46.2, 13.9. HRMS (ESI-TOF) calcd for $\text{C}_{12}\text{H}_{12}\text{ClNO}_2\text{Na} [\text{M}+\text{Na}]^+$: 260.0449, found: 260.0448.




(E)-3-(1-(4-(trifluoromethyl)phenyl)prop-1-en-1-yl)oxazolidin-2-one(3se')

Brown solid, mp 46.7-47.6 °C, 0.705g (26% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.6 (d, J = 8.2 Hz, 2H), 7.4 (d, J = 7.6 Hz, 2H), 5.9 (q, J = 7.3 Hz, 1H), 4.4 – 4.3 (m, 2H), 3.7 – 3.5 (m, 2H), 1.7 (d, J = 7.3 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.5, 138.3, 134.3, 130.2 (q, J = 33.7, 32.9 Hz), 125.5 (q, J = 4.3 Hz), 123.6 (q, J = 273.1 Hz), 121.3, 61.7, 46.2, 13.8. ^{19}F NMR (377 MHz, Chloroform-*d*) δ -62.7. HRMS (ESI-TOF) calcd for $\text{C}_{13}\text{H}_{12}\text{F}_3\text{NO}_2\text{Na} [\text{M}+\text{Na}]^+$: 294.0712, found: 294.0725.




(E)-3-(1-(4-methoxyphenyl)prop-1-en-1-yl)oxazolidin-2-one(3sf')

White solid, mp 54.7-55.8 °C, 1.072g (46% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.18 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.85 (q, J = 7.2 Hz, 1H), 4.34 – 4.22 (m, 2H), 3.80 (s, 3H), 3.57 – 3.44 (m, 2H), 1.72 (d, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 159.4, 156.7, 134.8, 130.2, 126.6, 119.8, 113.9, 61.6, 55.3, 46.2, 13.9. HRMS (ESI-TOF) calcd for $\text{C}_{13}\text{H}_{15}\text{NO}_3\text{Na} [\text{M}+\text{Na}]^+$: 256.0944, found: 256.0940.



(E)-3-(1-(4-chlorophenyl)-2-phenylvinyl)oxazolidin-2-one(3sg')

White solid, mp 98.2-99.9 °C, 0.807g (27% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.33 – 7.27 (m, 2H), 7.25 – 7.20 (m, 2H), 7.18 – 7.08 (m, 3H), 7.01 – 6.93 (m, 2H), 6.75 (s, 1H), 4.38 (td, J = 7.8, 1.0 Hz, 2H), 3.69 – 3.62 (m, 2H). $^{13}\text{C}\{\text{1H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.0, 135.2, 134.8, 134.6, 132.9, 129.3, 129.2, 128.2, 127.1, 123.1, 61.7, 46.1. HRMS (ESI-TOF) calcd for $\text{C}_{17}\text{H}_{14}\text{ClNO}_2\text{Na} [\text{M}+\text{Na}]^+$: 322.0611, found: 322.0614.










(E)-3-(2-(4-chlorophenyl)-1-phenylvinyl)oxazolidin-2-one(3sh')

White solid, mp 133.6–136.4 °C, 1.196g (40% yield). ^1H NMR (400 MHz, Chloroform-*d*) δ 7.39 – 7.32 (m, 3H), 7.30 – 7.23 (m, 2H), 7.09 – 7.02 (m, 2H), 6.89 – 6.84 (m, 2H), 6.79 (s, 1H), 4.39 – 4.31 (m, 2H), 3.63 – 3.55 (m, 2H). $^{13}\text{C}\{\text{H}\}$ NMR (101 MHz, Chloroform-*d*) δ 156.1 , 136.2 , 134.2 , 134.1 , 132.5 , 130.5 , 129.6 , 129.2 , 129.2 , 128.3 , 121.3 , 61.7 , 46.0 . HRMS (ESI-TOF) calcd for $\text{C}_{17}\text{H}_{14}\text{ClNO}_2\text{Na} [\text{M}+\text{Na}]^+$: 322.0611, found: 322.0618.

Table S6: *E* and *Z* isomers ratio of the Lewis Acid reactions before isolation of the products.


Entry	Enamide	d.r. (<i>E</i> : <i>Z</i>)	Entry	Enamide	d.r. (<i>E</i> : <i>Z</i>)
1		97:3	14		99:1
2		98:2	15		98:2
3		99:1	16		90:10
4		99:1	17		96:4
5		99:1	18		95:5
6		99:1	19		95:5
7		80:20	20		95:5
8		85:15	21		96:4
9		99:1	22		93:7
10		99:1	23		92:8

Entry	Enamide	d.r. (<i>E</i> : <i>Z</i>)	Entry	Enamide	d.r. (<i>E</i> : <i>Z</i>)
11		99:1	24		93:7
12		99:1	25		99:1
13		95:5	26		95:5



¹H NMR (500 MHz, CD₂Cl₂). Stacked spectra recorded over time of the Lewis Acid catalyzed reaction.

Figure S1 Kinetic study of Lewis Acid catalyzed reaction.



(Irradiated resonance 6.60-6.57, difference at *i*-pr chain.) (Z)-geometry of the double bond
Figure S2 NOE experiment to determine the geometry of the double bond

2. (*E*)- and (*Z*)- isomer energies.

Computational Details

The Gaussian 09² package was used for all calculations carried out. The two isomers were first optimized using B3LYP/6-31+g(d).³ The optimised 6-31+g(d) structures were then further optimized at B3LYP/6-311++g(d). The relative energies that are presented were obtained from the optimized gas phase calculations. The XYZ coordinates of the calculated structures are also listed below. All computations were carried out using the computational cluster resources at the National Supercomputer Centre based at Linkoping University, Sweden and at the Center for High Performance Computing, South Africa.

Gas phase energies

Structure	Relative energy/kcal mol ⁻¹
Z_isomer	0
E_isomer	2.21

XYZ coordinates of structures calculated


Z_isomer (Energy = -749,111839 Hartrees, 0 kcal mol⁻¹)
C,-5.0864436615,0.4323134834,-1.0159199977
C,-3.7277067957,0.445139407,-0.7142416175
C,-3.2250877054,-0.2937555965,0.3675562948
C,-4.1269793923,-1.0292564074,1.1485952065
C,-5.4867562314,-1.0437193899,0.8458706003
C,-5.9720222109,-0.3126640726,-0.2370752326
H,-5.4539505413,0.9985488489,-1.8659219515
H,-3.0431603589,1.0086596599,-1.340491732
H,-6.169405319,-1.6178759561,1.464422145
H,-7.0317314603,-0.3198507162,-0.470763803
C,-1.7670889808,-0.3034936641,0.662743231
C,-1.0924948689,-1.4253406895,0.9565171855
H,-1.6549140149,-2.3553131512,0.9087978842
C,0.3609979803,-1.5506178174,1.2961747288
H,0.9143942271,-1.8303538003,0.3898861286
H,0.764700011,-0.5779027477,1.5951275173
C,0.6289924614,-2.589843109,2.3965969807
H,0.2179864897,-3.5588779579,2.0875670048
H,0.084951304,-2.3066426119,3.3058221088
C,2.1172907116,-2.7453483279,2.7144799824
H,2.5531524963,-1.8022558996,3.0593696216
H,2.2827421562,-3.4903995449,3.4978115088
H,2.6814453522,-3.062261512,1.8318512194
H,-3.7589046093,-1.5804749428,2.0078571119
N,-1.1014076951,0.9538785865,0.5709522896

C,-0.124853905,1.2469617524,-0.3632322647
 C,-1.5714989484,2.1600843046,1.2469248871
 C,-0.4247649213,3.1277090812,0.9247590477
 H,-2.5327203989,2.4980144982,0.845105676
 H,-0.7572896049,4.1349326758,0.677672179
 O,0.3706033138,0.518402281,-1.1789820237
 O,0.2160766773,2.5691460034,-0.234835231
 H,-1.6871243223,1.9918075734,2.3196240275
 H,0.3094584556,3.1764733791,1.7335080567

E_isomer (Energy = -749,108320 Hartrees, 2.21 kcal mol⁻¹)


C,-5.7015673031,-0.8331938926,0.4241750141
 C,-4.4196867085,-0.9649065665,0.9558363577
 C,-3.3402658403,-0.2603180194,0.4078101358
 C,-3.5818263018,0.5958801358,-0.6771304764
 C,-4.8611399469,0.7265146642,-1.2098531931
 C,-5.9263065673,0.0117530499,-0.6607906709
 H,-6.5259937907,-1.3858912246,0.8635343894
 H,-4.2527058138,-1.610756658,1.8116355808
 H,-5.0265700829,1.3832626857,-2.0580688079
 H,-6.9241355871,0.1158360861,-1.0745706132
 C,-1.966413588,-0.3912238404,0.9682581304
 C,-1.2960057857,-1.5400730096,1.137556836
 H,-2.7555243748,1.1465515094,-1.1161826851
 N,-1.3246840939,0.8429232393,1.2945995234
 C,-0.1395978676,1.2756437678,0.7270506286
 C,-1.973631316,1.9077101784,2.0535889761
 C,-0.8034714533,2.8846691782,2.2294424121
 H,-2.8077491954,2.3475454587,1.4961599085
 H,-1.0823535125,3.9297372009,2.1018870627
 O,0.5741942577,0.7027797389,-0.0506226155
 O,0.1274530692,2.5384921718,1.1905397628
 H,-2.3546033502,1.5374607852,3.007770835
 H,-0.3052662099,2.7579262437,3.1944678059
 C,-1.7057717569,-2.9115327552,0.6870577586
 H,-1.7986957146,-3.5663875363,1.5655216436
 H,-2.6910688734,-2.8827917762,0.2169381817
 C,-0.7015520197,-3.5567769448,-0.2941093461
 H,-1.1390502299,-4.4980098323,-0.6468703759
 H,-0.6023390462,-2.9138601212,-1.1751880179
 C,0.6820733168,-3.8363132728,0.2979120484
 H,1.3127961176,-4.3664778951,-0.4211135772
 H,1.2076302593,-2.9168403894,0.5670622947
 H,0.6136306906,-4.4599215093,1.196136905
 H,-0.309492361,-1.4597841204,1.5851241477

4. NMR spectra of new compounds




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3sa**


ES29 P1 Chir.HPLC-190519-2.10.fid





ES29 chir.C-190520-2.10.fid




¹H and ¹³C{¹H} NMR spectra of **3sb**




¹H and ¹³C{¹H} NMR spectra of **3sc**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3sd**



^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3se**




^{19}F NMR spectra of **3se**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3sf**


SK-180424-10-Pr-enamide.10.fid




SK-180419-10-103.10.fid




¹H and ¹³C{¹H} NMR spectra of 3a




¹H and ¹³C{¹H} NMR spectra of **3b**





¹H and ¹³C{¹H} NMR spectra of **3c**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3d**




¹⁹F NMR spectra of **3d**




¹H and ¹³C{¹H} NMR spectra of 3e




¹⁹F NMR spectra of **3e**




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3f**



¹H and ¹³C{¹H} NMR spectra of 3g







¹H and ¹³C{¹H} NMR spectra of **3h**




¹H and ¹³C{¹H} NMR spectra of **3i**


JJ-SK-10-92 20180421.10.fid




¹H and ¹³C{¹H} NMR spectra of **3j**




¹H and ¹³C{¹H} NMR spectra of 3m




¹⁹F NMR spectra of **3m**




¹H and ¹³C{¹H} NMR spectra of 3p




¹⁹F NMR spectra of **3p**







¹H and ¹³C{¹H} NMR spectra of **3sa'**




¹H and ¹³C{¹H} NMR spectra of 3sb'




YJ-20190526-5-26-3/10



¹H and ¹³C{¹H} NMR spectra of 3sd'




¹H and ¹³C{¹H} NMR spectra of 3se'




¹⁹F NMR spectra of **3se'**


YJ-20190603-5-36-2/10





YJ-20190603-5-36-2/11




¹H and ¹³C{¹H} NMR spectra of **3sf**









^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of 3a'




¹H and ¹³C{¹H} NMR spectra of 3b'




¹H and ¹³C{¹H} NMR spectra of 3c'




¹H and ¹³C{¹H} NMR spectra of 3d'




¹⁹F NMR spectra of **3d'**




¹H and ¹³C{¹H} NMR spectra of 3e'




¹⁹F NMR spectra of **3e'**





¹H and ¹³C{¹H} NMR spectra of 3f




^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of **3g'**




¹H and ¹³C{¹H} NMR spectra of 3h'




¹H and ¹³C{¹H} NMR spectra of 3i'








¹H and ¹³C{¹H} NMR spectra of 3k'




¹H and ¹³C{¹H} NMR spectra of 3I'





¹H and ¹³C{¹H} NMR spectra of 3m'




¹⁹F NMR spectra of **3m'**









¹H and ¹³C{¹H} NMR spectra of 3p'




¹⁹F NMR spectra of **3p'**





¹H and ¹³C{¹H} NMR spectra of 3q'




¹H and ¹³C{¹H} NMR spectra of **3r'**



¹H and ¹³C{¹H} NMR spectra of 3s'



^1H and $^{13}\text{C}\{1\text{H}\}$ NMR spectra of **5a**



¹H and ¹³C{¹H} NMR spectra of 5c

5. references

1. Yang, Y.; Wang, L.; Zhang, F.; Zhu, G., Preparation of (*Z*)- α,β -Disubstituted Enamides via Palladium-Catalyzed Addition of Boronic Acids to Ynamides. *J. Org. Chem.* **2014**, 79 (19), 9319-9324.
2. Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2009.
3. W. Koch, M. C. A. Holthausen, Chemist's Guide to Density Functional Theory. (2nd Ed), **2001**, Wiley-Vch Weinheim.